Mitsubishi Chemical : Notice Regarding Changes in Specified SubsidiariesNEW

About this update from Mitsubishi Chemical Group Corporation

April 30, 2026 Company name: Mitsubishi Chemical Group Corporation Representative: Manabu Chikumoto Representative Corporate Executive Officer, President and Chief Executive Officer Listed on the Prime Market of TSE (stock code: 4188 Contact: [Press inquiries] Corporate Communications Office Tel: (+81) (0)3-6748-7140 [IR inquiries] Investor Relations Office Tel: (+81) (0)3-6748-7120 Notice Regarding Changes in Specified Subsidiaries Mitsubishi Chemical Group Corporation (hereinafter "MCG") hereby announces that there has been a change in our specified subsidiary as detailed below. Reason for the Change Nippon Sanso Holdings Corporation (TSE Prime: 4091; Head office: Shinagawa-ku, Tokyo; Representative Director, President CEO: Toshihiko Hamada; hereinafter "NSHD"), a consolidated subsidiary of MCG, reached an agreement to acquire Esteve Teijin Healthcare, S.L., which was under Corporación Químico-Farmacéutica Esteve and Teijin Holdings Europe B.V. and operates home healthcare services business in Spain. The acquisition was made through Oximesa S.L.U., the Spanish subsidiary of its European subsidiary, Nippon Sanso Euro-Holding S.L.U. (formerly Nippon Gases Euro-Holding S.L.U.). On March 3, 2026, NSHD completed the procedures to acquire the shares of the target company based on this agreement and subsequently renamed the acquired company to "Nippon Sanso Homecare España, S.L.U.". After acquiring the shares of the company and making it a subsidiary, NSHD conducted a review of the company's past capital transactions and it has been determined that Nippon Sanso Homecare España, S.L.U., which became a consolidated subsidiary, has become MCG's specified subsidiary because its capital corresponds to an amount equivalent to 10% or more of MCG's capital. Overview of the Subsidiary Subject to Change (1) Name Nippon Sanso Homecare España, S.L.U. (2) Location Passeig del Ferrocarril, 369, P. I. Camí Ral, 08860 Castelldefels, Barcelona, Spain (3) Name and title of representative Director Justin Corcho(Mr.) (4) Line of business Home healthcare services business (5) Capital EUR 35.7 million (6) Establishment February 2009 (7) Major shareholder(s) and ownership Oximesa S.L.U. 100% percentage (8) Relationship between the listed company and the relevant company Capital Relationship The company is a 100% owned subsidiary of Oximesa S.L.U., which is NSHD's European subsidiary. Personnel Relationship None Business Relationship None (9) Operating results and financial status of the relevant company for the last three years Fiscal Year Fiscal Year ended December 2022 Fiscal Year ended December 2023 Fiscal Year ended June December 2024 Net Assets 12 million EUR 14 million EUR 36 million EUR Total Assets 47 million EUR 61 million EUR 59 million EUR Revenue 33 million EUR 37 million EUR 40 million EUR Operating Profit 4 million EUR 3 million EUR 3 million EUR Net Profit 3 million EUR 2 million EUR 2 million EUR Date of Transfer March 3, 2026 Future Outlook The impact of this matter has been incorporated into the full-year consolidated earnings forecast for the fiscal year ending March 2026, announced on February 5, 2026.

View stock analysis, news, and events for Mitsubishi Chemical Group Corporation